Pathological Complete Response Following Neoadjuvant Tislelizumab Monotherapy in Treatment-Naive Locally Advanced, MMR-Deficient/MSI-High Ascending Colon Cancer: A Case Report

Although recent trials started the use of neoadjuvant immunotherapy (NIT) in instability-high (MSI-H) or mismatch repair deficient (dMMR) early-stage or locally advanced colorectal cancer (LACRC), little data on the treatment strategy of NIT has been shown, and whether the tirelizumab mono-immune ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Hei, Yue, Yang, Ruixia, Kong, Shengnan, Zhang, Hongmei, Chen, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821431/
https://www.ncbi.nlm.nih.gov/pubmed/36615039
http://dx.doi.org/10.3390/jcm12010240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821431/
https://www.ncbi.nlm.nih.gov/pubmed/36615039
http://dx.doi.org/10.3390/jcm12010240

Ejemplares similares